整合血栓弹力图联合血小板图指导新冠肺炎相关凝血病的精准治疗、避免并发症并改善生存
该前瞻性研究纳入100例入住800张床位三级医院的新冠患者,入院时行血栓弹力图联合血小板图检测,由治疗医生选择是否按预设算法管理。血小板高活性与血栓/缺血并发症相关,严重血小板减少一律致命。结论提示血栓弹力图联合血小板图能更好刻画新冠凝血异常谱,可能指导个体化治疗。
要点
- 非算法指导组较算法指导组死亡风险增加(RR=7.7,p<0.0001),60.7% vs 5.6%死亡。
- 血栓弹力图联合血小板图指导的抗血小板治疗使死亡率降低82%(p=0.0002)。
- 非算法指导使用抗因子药物(肝素/依诺肝素)者死亡风险增加10.3倍(p=0.0001)。
- 血小板高活性(最大振幅-花生四烯酸/二磷酸腺苷>50分钟)伴或不伴血小板增多与血栓/缺血并发症相关;严重血小板减少(血小板计数<100,000/μL)一律致命。
适用人群与场景
- 纳入100例入住800张床位三级医院的新冠患者,入院时行血栓弹力图联合血小板图检测并前瞻性随访。
- 原文未明确排除人群。
诊断标准与关键阈值
- 血小板高活性定义为最大振幅-花生四烯酸/二磷酸腺苷>50分钟,伴或不伴血小板增多,与血栓/缺血并发症相关。
- 严重血小板减少定义为血小板计数<100,000/μL,原文称一律致命。
- 出血并发症见于因子活性降低(反应时间>8分钟)。
处置流程与药物剂量
- 第一步:新冠患者入院时行血栓弹力图联合血小板图检测。
- 第二步:治疗医生可选择按预设算法管理,包括随访血栓弹力图联合血小板图检测。
- 第三步:根据结果给予血栓弹力图联合血小板图指导的抗血小板治疗;原文未给出具体药物、剂量、途径和疗程。
- 原文未给出抗凝药物的具体剂量、途径、频次或目标值。
红旗征与不能漏的情况
- 血小板高活性(最大振幅-花生四烯酸/二磷酸腺苷>50分钟)提示血栓/缺血并发症风险。
- 严重血小板减少(血小板计数<100,000/μL)原文称一律致命。
- 反应时间>8分钟提示因子活性降低,与出血并发症相关。
- 非算法指导使用抗因子药物(肝素/依诺肝素)者死亡风险增加10.3倍。
研究设计与关键结果
- 前瞻性研究,单中心800张床位三级医院,纳入100例新冠患者,入院时行血栓弹力图联合血小板图检测。
- 分组:算法指导组(按血栓弹力图联合血小板图算法管理)vs 非算法指导组(未按该方案治疗)。
- 非算法指导组较算法指导组:机械通气RR=10.9(p<0.0001)、急性肾损伤RR=2.3(p=0.0017)、透析RR=7.8(p<0.0001)、死亡RR=7.7(p<0.0001)。
- 血栓弹力图联合血小板图指导的抗血小板治疗使死亡率降低82%(p=0.0002)。
- 非算法指导使用抗因子药物(肝素/依诺肝素)者死亡风险增加10.3倍(p=0.0001)。
- D-二聚体、C反应蛋白和铁蛋白在危重患者(非存活者、急性肾损伤、肺衰竭)中显著升高,但不能区分凝血病与非凝血病患者。
证据类型、等级与局限
- 证据类型:前瞻性观察性研究(单中心,样本量100例)。
- 局限:单中心、样本量小、非随机分组(治疗由医生选择),原文未提及盲法。
对床旁实践的改变
- 对新冠凝血病患者,可考虑用血栓弹力图联合血小板图指导治疗,而非经验性使用肝素/依诺肝素抗凝。
- 血小板高活性(最大振幅-花生四烯酸/二磷酸腺苷>50分钟)提示需考虑抗血小板治疗;严重血小板减少(<100,000/μL)提示预后极差。
- 反应时间>8分钟提示出血风险,需关注因子活性。
- 原文未明确适用与不适用人群的排除标准,临床决策需结合个体情况。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Coagulopathy of coronavirus disease 2019 is largely described as hypercoagulability, yet both thrombotic and hemorrhagic complications occur. Although therapeutic and prophylactic anticoagulant interventions have been recommended, empiric use of antifactor medications (heparin/enoxaparin) may result in hemorrhagic complications, including death. Furthermore, traditional (antifactor) anticoagulation does not address the impact of overactive platelets in coronavirus disease 2019. The primary aim was to evaluate if algorithm-guided thromboelastography with platelet mapping could better characterize an individual's coronavirus disease 2019-relatedcoagulopathic state and, secondarily, improve outcomes.
DESIGN SETTING AND PATIENTS: Coronavirus disease 2019 patients (n = 100), receiving thromboelastography with platelet mapping assay upon admission to an 800-bed tertiary-care hospital, were followed prospectively by a hospital-based thromboelastography team. Treating clinicians were provided with the option of using a pre-established algorithm for anticoagulation, including follow-up thromboelastography with platelet mapping assays. Two groups evolved: 1) patients managed by thromboelastography with platelet mapping algorithm (algorithm-guided-thromboelastography); 2) those treated without thromboelastography with platelet mapping protocols (non-algorithm-guided). Outcomes included thrombotic/hemorrhagic complications, pulmonary failure, need for mechanical ventilation, acute kidney injury, dialysis requirement, and nonsurvival.
INTERVENTIONS: Standard-of-care therapy with or without algorithm-guided-thromboelastography support.
MEASUREMENTS AND MAIN RESULTS: Although d-dimer, C-reactive protein, and ferritin were elevated significantly in critically ill (nonsurvivors, acute kidney injury, pulmonary failure), they did not distinguish between coagulopathic and noncoagulopathic patients. Platelet hyperactivity (maximum amplitude-arachidonic acid/adenosine diphosphate > 50 min), with or without thrombocytosis, was associated with thrombotic/ischemic complications, whereas severe thrombocytopenia (platelet count < 100,000/μL) was uniformly fatal. Hemorrhagic complications were observed with decreased factor activity (reaction time > 8 min). Non-algorithm-guided patients had increased risk for subsequent mechanical ventilation (relative risk = 10.9; p < 0.0001), acute kidney injury (relative risk = 2.3; p = 0.0017), dialysis (relative risk = 7.8; p < 0.0001), and death (relative risk = 7.7; p < 0.0001), with 17 of 28 non-algorithm-guided patients (60.7%) dying versus four algorithm-guided-thromboelastography patients (5.6%) (p < 0.0001). Thromboelastography with platelet mapping-guided antiplatelet treatment decreased mortality 82% (p = 0.0002), whereas non-algorithm-guided (compared with algorithm-guided-thromboelastography) use of antifactor therapy (heparin/enoxaparin) resulted in 10.3-fold increased mortality risk (p = 0.0001).
CONCLUSIONS: Thromboelastography with platelet mapping better characterizes the spectrum of coronavirus disease 2019 coagulation-related abnormalities and may guide more tailored, patient-specific therapies in those infected with coronavirus disease 2019.
参考来源
- Hranjec T, Estreicher M, Rogers B, et al. Integral Use of Thromboelastography With Platelet Mapping to Guide Appropriate Treatment, Avoid Complications, and Improve Survival of Patients With Coronavirus Disease 2019-Related Coagulopathy. Crit Care Explor. 2020. PMID: 33381763. doi:10.1097/CCE.0000000000000287
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。